These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 15896827)

  • 1. Effect of valsartan on monocyte/endothelial cell activation markers and adiponectin in hypertensive patients with type 2 diabetes mellitus.
    Nomura S; Shouzu A; Omoto S; Nishikawa M; Fukuhara S; Iwasaka T
    Thromb Res; 2006; 117(4):385-92. PubMed ID: 15896827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of nifedipine on adiponectin in hypertensive patients with type 2 diabetes mellitus.
    Nomura S; Inami N; Kimura Y; Omoto S; Shouzu A; Nishikawa M; Iwasaka T
    J Hum Hypertens; 2007 Jan; 21(1):38-44. PubMed ID: 17051237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benidipine improves oxidized LDL-dependent monocyte and endothelial dysfunction in hypertensive patients with type 2 diabetes mellitus.
    Nomura S; Shouzu A; Omoto S; Nishikawa M; Iwasaka T
    J Hum Hypertens; 2005 Jul; 19(7):551-7. PubMed ID: 15829999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation and association between plasma platelet-, monocyte- and endothelial cell-derived microparticles in hypertensive patients with type 2 diabetes mellitus.
    Nomura S; Inami N; Shouzu A; Urase F; Maeda Y
    Platelets; 2009 Sep; 20(6):406-14. PubMed ID: 19658004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of valsartan and indapamide on plasma cytokines in essential hypertension.
    Xie QY; Wang YJ; Sun ZL; Yang TL
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2006 Oct; 31(5):629-34. PubMed ID: 17062919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
    Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of efonidipine on platelet and monocyte activation markers in hypertensive patients with and without type 2 diabetes mellitus.
    Nomura S; Kanazawa S; Fukuhara S
    J Hum Hypertens; 2002 Aug; 16(8):539-47. PubMed ID: 12149659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term treatment with nifedipine modulates procoagulant marker and C-C chemokine in hypertensive patients with type 2 diabetes mellitus.
    Nomura S; Shouzu A; Omoto S; Nishikawa M; Iwasaka T
    Thromb Res; 2005; 115(4):277-85. PubMed ID: 15668187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating adhesion molecules levels in type 2 diabetes mellitus and hypertension.
    Boulbou MS; Koukoulis GN; Makri ED; Petinaki EA; Gourgoulianis KI; Germenis AE
    Int J Cardiol; 2005 Jan; 98(1):39-44. PubMed ID: 15676164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The angiotensin II receptor antagonist valsartan enhances lipoprotein lipase mass in preheparin serum in type 2 diabetes with hypertension.
    Saiki A; Ohira M; Endo K; Koide N; Oyama T; Murano T; Miyashita Y; Shirai K
    Diabetes Res Clin Pract; 2006 Dec; 74(3):242-8. PubMed ID: 16713009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus.
    Hollenberg NK; Parving HH; Viberti G; Remuzzi G; Ritter S; Zelenkofske S; Kandra A; Daley WL; Rocha R
    J Hypertens; 2007 Sep; 25(9):1921-6. PubMed ID: 17762658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of valsartan alone versus valsartan/simvastatin combination on ambulatory blood pressure, C-reactive protein, lipoproteins, and monocyte chemoattractant protein-1 in patients with hyperlipidemia and hypertension.
    Rajagopalan S; Zannad F; Radauceanu A; Glazer R; Jia Y; Prescott MF; Kariisa M; Pitt B
    Am J Cardiol; 2007 Jul; 100(2):222-6. PubMed ID: 17631074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Levels of soluble adhesion molecules among normal and hypertensive type 2 diabetic patients].
    Rubio-Guerra AF; Vargas-Robles H; Medina-Santillán R; Escalante-Acosta BA
    Gac Med Mex; 2008; 144(1):11-4. PubMed ID: 18619052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the effects of valsartan and felodipine on plasma leptin and insulin sensitivity in hypertensive obese patients.
    Fogari R; Derosa G; Zoppi A; Rinaldi A; Lazzari P; Fogari E; Mugellini A; Preti P
    Hypertens Res; 2005 Mar; 28(3):209-14. PubMed ID: 16097363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Valsartan in patients with arterial hypertension and type 2 diabetes mellitus. The lapaval study].
    Rodríguez Pérez JC; Novoa Novoa J; Caballero A; Anabitarte A; Plaza C; Palop L; Rodríguez Esparragón F
    Nefrologia; 2005; 25(5):500-8. PubMed ID: 16392299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of monocyte-derived microparticles in patients with Type II diabetes mellitus.
    Omoto S; Nomura S; Shouzu A; Nishikawa M; Fukuhara S; Iwasaka T
    Diabetologia; 2002 Apr; 45(4):550-5. PubMed ID: 12032632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute effects of valsartan on insulin sensitivity in obese, non-hypertensive subjects with and without type 2 diabetes.
    Luzio SD; Dunseath G; Owens DR
    Horm Metab Res; 2002 May; 34(5):271-4. PubMed ID: 12063642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of valsartan, an angiotensin II receptor blocker, on markers of oxidation and glycation in Japanese type 2 diabetic subjects: blood pressure-independent effect of valsartan.
    Saisho Y; Komiya N; Hirose H
    Diabetes Res Clin Pract; 2006 Nov; 74(2):201-3. PubMed ID: 16737758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of valsartan and captopril on lipid parameters in patients with type II diabetes mellitus and nephropathy.
    Cheung R; Lewanczuk RZ; Rodger NW; Huff MW; Oddou-Stock P; Botteri F; Pecher E; Muirhead N
    Int J Clin Pract; 1999 Dec; 53(8):584-92. PubMed ID: 10692751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is the reno-protective effect of valsartan dose dependent? A comparative study of 80 and 160 mg day(-1).
    Saikawa T; Sasaki J; Biro S; Kono S; Otonari T; Ikeda Y;
    Hypertens Res; 2010 Sep; 33(9):886-91. PubMed ID: 20555331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.